AIFA promotes a randomized clinical trial to assess the effectiveness of monoclonal antibodies

Aggiornamento: Estensione automatica della scadenza dei certificati GMP durante la pandemia da COVID-19 (15/01/2021)

AIFA publishes the COVID-19 vaccines FAQS on Pharmacovigilance

EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca

Extra dose from vials of Comirnaty COVID-19 vaccine

COVID-19: AIFA authorizes Moderna vaccine

EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU

Report on COVID-19 vaccines

Update on rolling review of AstraZeneca’s COVID-19 vaccine

Procedure for submitting applications for marketing vaccines (State control for each batch) for COVID-19

AIFA, at least 6 doses can be obtained from each vial of BioNTech/Pfizer vaccine

Useful information and answers to questions about the COMIRNATY vaccine for COVID-19

AIFA recommendations on hydroxycloroquine

BioNTech/Pfizer vaccine authorised Answers to frequently asked questions on AIFA’s website

Use of Bamlanivimab monoclonal antibody in Italy for the treatment of COVID-19: no free of charge offer from Eli Lilly, just a sale approval request

EMA recommends first COVID-19 vaccine for authorisation in the EU

Update on assessment of marketing authorisation application for Moderna’s mRNA-1273 COVID-19 vaccine

Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application

AIFA establishes the Scientific Committee for monitoring COVID-19 vaccines

Guidelines on the treatment of COVID-19 patients